Preliminary evidence from the phase II CAPTAIN study demonstrated that camrelizumab monotherapy achieved a 28.2% objective response rate (ORR) in heavily pretreated recurrent/metastatic NPC, with biomarker analysis suggesting MHC cell density and PD-L1 expression may predict response (23). Here, CD274 is linked to nasopharyngeal carcinoma.